Drug delivery systems in the treatment of African trypanosomiasis infections

Bibliography

• WHO. The world health report. World Health Organization, Geneva; 1999
   Google Scholar
• Brun R, Blum J, Chappuis F, Human African trypanosomiasis. Lancet 2009;375(9709):148-59
   PubMed Web of Science ®Google Scholar
• Barrett MP, Boykin DW, Brun R, Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007;152(8):1155-71
   PubMed Web of Science ®Google Scholar
• Burchmore RJ, Ogbunude PO, Enanga B, Chemotherapy of human African trypanosomiasis. Curr Pharm Des 2002;8(4):256-67
   PubMedGoogle Scholar
• Barrett MP. Problems for the chemotherapy of human African trypanosomiasis. Curr Opin Infect Dis 2000;13(6):647-51
   PubMed Web of Science ®Google Scholar
• Torreele E, Bourdin Trunz B, Tweats D, Fexinidazole–a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2006;4(12):e923
   Google Scholar
• Yun O, Priotto G, Tong J, NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010;4(5):e720
   PubMed Web of Science ®Google Scholar
• Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007;59(6):505-21
   PubMed Web of Science ®Google Scholar
• Miller EN, Allan LM, Turner MJ. Topological analysis of antigenic determinants on a variant surface glycoprotein of Trypanosoma brucei. Mol Biochem Parasitol 1984;13(1):67-81
   PubMed Web of Science ®Google Scholar
• Jennings FW, Gray GD. Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol 1983;7:147-54
   PubMedGoogle Scholar
• Jennings FW, Hunter CA, Kennedy PG, Chemotherapy of Trypanosoma brucei infection of the central nervous system: the use of a rapid chemotherapeutic regimen and the development of post-treatment encephalopathies. Trans R Soc Trop Med Hyg 1993;87(2):224-6
   PubMed Web of Science ®Google Scholar
• Kinabo LD. Pharmacology of existing drugs for animal trypanosomiasis. Acta Trop 1993;54(3-4):169-83
   PubMed Web of Science ®Google Scholar
• Williamson J. Chemotherapy and chemoprophylaxis of african trypanosomiasis. Exp Parasitol 1962;12:274-322
   PubMed Web of Science ®Google Scholar
• Pepin J, Milord F, Khonde A, Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 1994;88(4):447-52
   PubMed Web of Science ®Google Scholar
• Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 2010;137(14):1987-94
   PubMed Web of Science ®Google Scholar
• Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001;6(5):390-400
   PubMed Web of Science ®Google Scholar
• Carter NS, Berger BJ, Fairlamb AH. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 1995;270(47):28153-7
   PubMed Web of Science ®Google Scholar
• Senior JC. Fate and behaviour of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carrier Syst 1991;3:123-93
   Google Scholar
• Alving CR. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol Today 1986;2(4):101-7
   PubMedGoogle Scholar
• Campbell PI. Toxicity of some charged lipids used in liposome preparations. Cytobios 1983;37(145):21-6
   PubMedGoogle Scholar
• Szoka FC Jr, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother 1987;31(3):421-9
   PubMed Web of Science ®Google Scholar
• Kuboki N, Yokoyama N, Kojima N, Efficacy of dipalmitoylphosphatidylcholine liposome against African trypanosomes. J Parasitol 2006;92(2):389-93
   PubMed Web of Science ®Google Scholar
• Souto-Padron T, de Carvalho TU, Chiari E, Further studies on the cell surface charge of Trypanosoma cruzi. Acta Trop 1984;41(3):215-25
   PubMed Web of Science ®Google Scholar
• Tachibana H, Yoshihara E, Kaneda Y, In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes. Antimicrob Agents Chemother 1988;32(7):966-70
   PubMed Web of Science ®Google Scholar
• Yoshihara E, Tachibana H, Nakae T. Trypanocidal activity of the stearylamine-bearing liposome in vitro. Life Sci 1987;40(22):2153-9
   PubMed Web of Science ®Google Scholar
• Gruenberg J, Coral D, Knupfer AL, Interactions of liposomes with Trypanosoma brucei plasma membrane. Biochem Biophys Res Commun 1979;88(3):1173-9
   PubMed Web of Science ®Google Scholar
• Yongsheng Y, Yongchun O, Chengmai R, Trypanocidal value of liposomal diminazene in experimental Trypanosoma brucei evansi infection in mice. Vet Parasitol 1996;61(3-4):349-52
   PubMed Web of Science ®Google Scholar
• Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307(1):93-102
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-7
   PubMed Web of Science ®Google Scholar
• Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003;55(3):403-19
   PubMed Web of Science ®Google Scholar
• Gref R, Luck M, Quellec P, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18(3-4):301-13
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5(4):505-15
   PubMed Web of Science ®Google Scholar
• Tsivgoulis GM, Sotiropoulos DN, Ioannou PV. 1,2-Dihydroxypropyl-3-arsonic acid: a key intermediate for arsonolipids. Phosphorus, Sulfur and Silicon and the Related Elements 1991;57(3-4):189-93
   Web of Science ®Google Scholar
• Timotheatou D, Ioannou PV, Scozzafava A, Carbonic anhydrase interaction with lipothioars enites: a novel class of isozymes I and II inhibitors. Met Based Drugs 1996;3(6):263-8
   PubMedGoogle Scholar
• Antimisiaris SG, Ioannou PV, Loiseau PM. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. J Pharm Pharmacol 2003;55(5):647-52
   PubMed Web of Science ®Google Scholar
• Zagana P, Klepetsanis P, Ioannou PV, Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition. Biomed Pharmacother 2007;61(8):499-504
   PubMed Web of Science ®Google Scholar
• Zagana P, Haikou M, Klepetsanis P, In vivo distribution of arsonoliposomes: effect of vesicle lipid composition. Int J Pharm 2008;347(1-2):86-92
   PubMed Web of Science ®Google Scholar
• Piperoudi S, Ioannou PV, Frederik P, Arsonoliposomes: effect of lipid composition on their stability and morphology. J Liposome Res 2005;15(3-4):187-97
   PubMed Web of Science ®Google Scholar
• Piperoudi S, Fatouros D, Ioannou PV, Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles. Chem Phys Lipids 2006;139(2):96-106
   PubMed Web of Science ®Google Scholar
• Shafer SH, Williams CL. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment. Int J Oncol 2003;23(2):389-400
   PubMed Web of Science ®Google Scholar
• Na HK, Chang CC, Trosko JE. Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH(3), is mediated by inhibition of cytokinesis. Cancer Chemother Pharmacol 2003;51(3):209-15
   PubMed Web of Science ®Google Scholar
• Lux H, Heise N, Klenner T, Ether–lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether–lipid analogues in Leishmania. Mol Biochem Parasitol 2000;111(1):1-14
   PubMed Web of Science ®Google Scholar
• Croft SL, Coombs GH. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003;19(11):502-8
   PubMed Web of Science ®Google Scholar
• Croft SL, Seifert K, Duchene M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 2003;126(2):165-72
   PubMed Web of Science ®Google Scholar
• Lux H, Hart DT, Parker PJ, Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv Exp Med Biol 1996;416:201-11
   PubMedGoogle Scholar
• Papagiannaros A, Bories C, Demetzos C, Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed Pharmacother 2005;59(10):545-50
   PubMed Web of Science ®Google Scholar
• Atsriku C, Watson DG, Tettey JN, Determination of diminazene aceturate in pharmaceutical formulations by HPLC and identification of related substances by LC/MS. J Pharm Biomed Anal 2002;30(4):979-86
   PubMed Web of Science ®Google Scholar
• Thunemann AF, Schutt D, Sachse R, Complexes of poly(ethylene oxide)-block-poly(L-glutamate) and diminazene. Langmuir 2006;22(5):2323-8
   PubMed Web of Science ®Google Scholar
• Soliman GM, Winnik FM. Enhancement of hydrophilic drug loading and release characteristics through micellization with new carboxymethyldextran-PEG block copolymers of tunable charge density. Int J Pharm 2008;356(1-2):248-58
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Xiong C, Drug-polyionic block copolymer interactions for micelle formation: physicochemical characterisation. J Control Release 2001;75(3):249-58
   PubMed Web of Science ®Google Scholar
• Prompruk K, Govender T, Zhang S, Synthesis of a novel PEG-block-poly(aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier. Int J Pharm 2005;297(1-2):242-53
   PubMed Web of Science ®Google Scholar
• Dou H, Jiang M. Fabrication, characterization and drug loading of pH-dependent multi-morpho- logical nanoparticles based on cellulose. Polym Int 2007;56(7):1206-12
   Google Scholar
• Gibaud S, Gaia A, Astier A. Slow-release melarsoprol microparticles. Int J Pharm 2002;243(1-2):161-6
   PubMedGoogle Scholar
• Ben Zirar S, Astier A, Muchow M, Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 2008;70(2):649-56
   PubMed Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47(1):3-19
   PubMed Web of Science ®Google Scholar
• Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm 1995;41:2-13
   Web of Science ®Google Scholar
• ISO/TS 27687 IOfSTS. Nanotechnologies – terminology and definitions for nanoobjects- nanoparticle, nanofibre and nanoplate. International Organization for Standardisation 2008
   Google Scholar
• Brandenberger C, Rothen-Rutishauser B, Blank F, Particles induce apical plasma membrane enlargement in epithelial lung cell line depending on particle surface area dose. Respir Res 2009;10(1):22
   PubMedGoogle Scholar
• Leroueil-Le Verger M, Fluckiger L, Kim YI, Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998;46(2):137-43
   PubMed Web of Science ®Google Scholar
• Kim SY, Shin IG, Lee YM. Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and DL-lactide block copolymer as novel drug carriers. J Control Release 1998;56(1-3):197-208
   PubMed Web of Science ®Google Scholar
• Fernandez-Urrusuno R, Fattal E, Rodrigues JM, Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 1996;31(3):401-8
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70(1-2):1-20
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002;10(4):317-25
   PubMed Web of Science ®Google Scholar
• Jallouli Y, Paillard A, Chang J, Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm 2007;344(1-2):103-9
   PubMedGoogle Scholar
• Chang J, Jallouli Y, Barras A, Chapter 1 - Drug delivery to the brain using colloidal carriers. Prog Brain Res 2009;180:2-17
   PubMedGoogle Scholar
• Chang J, Jallouli Y, Kroubi M, Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009;379(2):285-92
   PubMed Web of Science ®Google Scholar
• Olbrich C, Gessner A, Schroder W, Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J Control Release 2004;96(3):425-35
   PubMed Web of Science ®Google Scholar
• Olbrich C, Gessner A, Kayser O, Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002;10(5):387-96
   PubMed Web of Science ®Google Scholar
• Gessner A, Olbrich C, Schroder W, The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 2001;214(1-2):87-91
   PubMed Web of Science ®Google Scholar
• Loiseau PM, Imbertie L, Bories C, Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations. Antimicrob Agents Chemother 2002;46(5):1597-601
   PubMed Web of Science ®Google Scholar
• Paillard A, Passirani C, Saulnier P, Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as ‘stealth’ cationic nanocarriers. Pharm Res 2010;27(1):126-33
   PubMed Web of Science ®Google Scholar
• Kroubi M, Dauloued S, Karembe H, Development of a nanoparticulate formulation of diminazene to treat African Trypanosomiasis. Nanotechnology 2010;21(50):505102-10
   PubMedGoogle Scholar
• Durand R, Paul M, Rivollet D, Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite 1997;4(4):331-6
   PubMed Web of Science ®Google Scholar
• Durand R, Paul M, Rivollet D, Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int J Parasitol 1997;27(11):1361-7
   PubMed Web of Science ®Google Scholar
• Fusai T, Boulard Y, Durand R, Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Parasite 1997;4(2):133-9
   PubMed Web of Science ®Google Scholar
• Fusai T, Deniau M, Durand R, Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. Parasite 1994;1(4):319-24
   PubMed Web of Science ®Google Scholar
• Paul M, Durand R, Boulard Y, Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 1998;5(6):481-90
   PubMed Web of Science ®Google Scholar
• Kulkarni RK, Moore EG, Hegyeli AF, Biodegradable poly(lactic acid) polymers. J Biomed Mater Res 1971;5(3):169-81
   PubMedGoogle Scholar
• Bazile DV, Ropert C, Huve P, Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992;13(15):1093-102
   PubMed Web of Science ®Google Scholar
• Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull (Tokyo) 1985;33(3):1195-201
   PubMed Web of Science ®Google Scholar
• Fricker G, Flaig RM. Bdellosomes US 2004062815;2004
   Google Scholar
• Flaig RM, Rosenkranz V, Wink M, Ktenate nanoparticles (bdellosomes): a novel strategy for delivering drugs to parasites or tumours. STP Pharm Sci 2005;15(1):59-63
   Google Scholar
• De Deken R, Geerts S, Kageruka P, Chemoprophylaxis of trypanosomiasis, due to Trypanosoma (Nannomonas) congolense, in rabbits using a slow release device containing homidium bromide. Ann Soc Belg Med Trop 1989;69(4):291-6
   PubMedGoogle Scholar
• Geerts S, De Deken R, Kageruka P, Evaluation of the efficacy of a slow release device containing homidium bromide in rabbits infected with Trypanosoma congolense. Vet Parasitol 1993;50(1-2):15-21
   PubMed Web of Science ®Google Scholar
• Kageruka P, Kabore H, Marcotty T, Comparative evaluation of the prophylactic effect of slow release devices containing homidium bromide and isometamidium on Trypanosoma congolense in rabbits. Vet Parasitol 1996;63(3-4):179-85
   PubMed Web of Science ®Google Scholar
• Geerts S, Kageruka P, De Deken R, Prophylactic effects of isometamidium- and ethidium-sustained release devices against Trypanosoma congolense in cattle. Acta Trop 1997;65(1):23-31
   PubMed Web of Science ®Google Scholar
• Geerts S, Diarra B, Eisler MC, Extension of the prophylactic effect of isometamidium against trypanosome infections in cattle using a biodegradable copolymer. Acta Trop 1999;73(1):49-58
   PubMed Web of Science ®Google Scholar
• Lemmouchi Y, Schacht E. Preparation and in vitro evaluation of biodegradable poly(epsilon-caprolactone-co-D,L lactide) (X-Y) devices containing trypanocidal drugs. J Control Release 1997;45:227-33
   Web of Science ®Google Scholar
• Lemmouchi Y, Schacht E, Lootens C. In vitro release of trypanocidal drugs from biodegradable implants based on poly(epsilon-caprolactone) and poly(D,L-lactide). J Control Release 1998;55(1):79-85
   PubMed Web of Science ®Google Scholar
• Lemmouchi Y, Schacht E, Kageruka P, Biodegradable polyesters for controlled release of trypanocidal drugs: in vitro and in vivo studies. Biomaterials 1998;19(20):1827-37
   PubMed Web of Science ®Google Scholar
• Bray PG, Barrett MP, Ward SA, Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 2003;19(5):232-9
   PubMed Web of Science ®Google Scholar
• de Koning HP, Anderson LF, Stewart M, The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes. Antimicrob Agents Chemother 2004;48(5):1515-19
   PubMed Web of Science ®Google Scholar
• Karvonen E, Kauppinen L, Partanen T, Irreversible inhibition of putrescine-stimulated S-adenosyl-L-methionine decarboxylase by berenil and pentamidine. Biochem J 1985;231(1):165-9
   PubMed Web of Science ®Google Scholar
• Balana-Fouce R, Garzon Pulido T, Ordonez-Escudero D, Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil). Biochem Pharmacol 1986;35(9):1597-600
   PubMed Web of Science ®Google Scholar
• Reinert KE. DNA multimode interaction with berenil and pentamidine; double helix stiffening, unbending and bending. J Biomol Struct Dyn 1999;17(2):311-31
   PubMed Web of Science ®Google Scholar
• Ainanshe OA, Jennings FW, Holmes PH. Isolation of drug-resistant strains of Trypanosoma congolense from the lower Shabelle region of southern Somalia. Trop Anim Health Prod 1992;24(2):65-73
   PubMed Web of Science ®Google Scholar
• Sinyangwe L, Delespaux V, Brandt J, Trypanocidal drug resistance in eastern province of Zambia. Vet Parasitol 2004;119(2-3):125-35
   PubMed Web of Science ®Google Scholar
• Lun ZR, Min ZP, Huang D, Cymelarsan in the treatment of buffaloes naturally infected with Trypanosoma evansi in south China. Acta Trop 1991;49(3):233-6
   PubMed Web of Science ®Google Scholar
• Boid R, Jones TW, Payne RC. Malic enzyme type VII isoenzyme as an indicator of suramin resistance in Trypanosoma evansi. Exp Parasitol 1989;69(4):317-23
   PubMed Web of Science ®Google Scholar
• Ndoutamia G, Moloo SK, Murphy NB, Derivation and characterization of a quinapyramine-resistant clone of Trypanosoma congolense. Antimicrob Agents Chemother 1993;37(5):1163-6
   PubMed Web of Science ®Google Scholar
• Hawking F, Sen AB. The trypanocidal action of homidium, quinapyramine and suramin. Br J Pharmacol Chemother 1960;15:567-70
   PubMed Web of Science ®Google Scholar
• Keiser J, Burri C. Physico-chemical properties of the trypanocidal drug melarsoprol. Acta Trop 2000;74(1):101-4
   PubMed Web of Science ®Google Scholar
• de Melo NF, Grillo R, Rosa AH, Interaction between nitroheterocyclic compounds with beta-cyclodextrins: phase solubility and HPLC studies. J Pharm Biomed Anal 2008;47(4-5):865-9
   PubMed Web of Science ®Google Scholar
• Paulino M, Iribarne F, Dubin M, The chemotherapy of Chagas' disease: an overview. Mini Rev Med Chem 2005;5(5):499-519
   PubMed Web of Science ®Google Scholar
• Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994;33:1-47
   PubMed Web of Science ®Google Scholar
• Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995;35:93-127
   PubMed Web of Science ®Google Scholar
• Vansterkenburg EL, Coppens I, Wilting J, The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop 1993;54(3-4):237-50
   PubMed Web of Science ®Google Scholar
• Bacchi CJ, Nathan HC, Hutner SH, Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980;210(4467):332-4
   PubMed Web of Science ®Google Scholar